PMID- 21925088
OWN - NLM
STAT- MEDLINE
DCOM- 20120110
LR  - 20110919
IS  - 1532-1924 (Electronic)
IS  - 1521-6926 (Linking)
VI  - 24
IP  - 3
DP  - 2011 Sep
TI  - Immunomodulatory strategies for relapse after haploidentical hematopoietic stem 
      cell transplantation in hematologic malignancy patients.
PG  - 351-8
LID - 10.1016/j.beha.2011.04.002 [doi]
AB  - Currently, human leukocyte antigen (HLA)-mismatched/haploidentical allografts 
      have been validated as an alternative stem cell source for patients who have no 
      immediate access to an HLA-matched related or unrelated donor. However, relapse 
      remains a challenge after HLA-mismatched/haploidentical hematopoietic stem cell 
      transplantation (HSCT) that is employed in the treatment of patients with 
      hematological malignancies. In recent years, newly developed immunomodulatory 
      strategies, which include prophylactic and therapeutic donor lymphocyte/natural 
      killer (NK) cell infusion, donor selection based on NK 
      alloreactivity/non-inherited maternal antigen (NIMA), immune reconstitution 
      promotion, and application of exogenous cytokines, have made it possible to 
      decrease the relapse rate and improve outcomes following haploidentical HSCT. 
      Further elucidation of the underlying mechanisms that govern leukemia stem cell 
      escape from immunosurveillance after haploidentical HSCT may broaden our 
      understanding and lead to therapies that control relapse.
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      No. 11 Xizhimen South Street, Beijing, China. xjhrm@medmail.com.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110625
PL  - Netherlands
TA  - Best Pract Res Clin Haematol
JT  - Best practice & research. Clinical haematology
JID - 101120659
RN  - 0 (Cytokines)
SB  - IM
MH  - Cytokines/*therapeutic use
MH  - Female
MH  - Hematologic Neoplasms/immunology/*prevention & control
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunologic Surveillance/drug effects/immunology
MH  - Immunotherapy, Adoptive/*methods
MH  - Killer Cells, Natural/immunology/*transplantation
MH  - Male
MH  - Neoplastic Stem Cells/immunology
MH  - Recurrence
MH  - Transplantation, Homologous
MH  - Tumor Escape/drug effects/immunology
EDAT- 2011/09/20 06:00
MHDA- 2012/01/11 06:00
CRDT- 2011/09/20 06:00
PHST- 2011/09/20 06:00 [entrez]
PHST- 2011/09/20 06:00 [pubmed]
PHST- 2012/01/11 06:00 [medline]
AID - S1521-6926(11)00038-7 [pii]
AID - 10.1016/j.beha.2011.04.002 [doi]
PST - ppublish
SO  - Best Pract Res Clin Haematol. 2011 Sep;24(3):351-8. doi: 
      10.1016/j.beha.2011.04.002. Epub 2011 Jun 25.